Dr Vojo Vukovic joins Synta
This article was originally published in Scrip
Synta Pharmaceuticals, a US biopharmaceutical company focused on discovering, developing and commercialising small-molecule drugs to treat severe medical conditions, has appointed Dr Vojo Vukovic vice-president of clinical research. He will be the medical lead for the company's most advanced oncology product candidate, elesclomol. Dr Vukovic has more than 15 years' experience in oncology drug development and joins from Pfizer, where he was global medical lead for Sutent and axitinib in a number of cancer indications.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.